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mediatorsAbstract It is sometimes asserted, as a matter of dogma, that a local treatment cannot have sys-
temic effects. However, treatment with radiotherapy directly localized on a tumour can profoundly
affect tumour cells in the other tissues far from the radiated part. In 1953, Dr. Mole called this sur-
prising phenomenon the ‘abscopal effect’. Since its discovery, very little is known about the exact
mechanism and the key mediators of this astonishing phenomenon and many other questions in this
context still remain unanswered. An understanding of this phenomenon could help to control the
fatal face of cancer which is metastasis, and this discovery in turn will introduce promising strategies
for treatment of advanced and not-curable cancers. Based on current information, we propose that
there is a particular molecule(s) or macromolecule(s) that mediate(s) the abscopal effect. We also
speculate that the frequency of the abscopal effect varies between different tumour types and the
newly discovered molecule(s) or macromolecule(s) can enhance/instigate the abscopal effect in those
tumour types that show a low frequency of the abscopal effect.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
The term ‘abscopal effect’ following radiotherapy was ﬁrst
named by Mole in 1953 [1]. Abscopal was derived from the La-
tin ab meaning ‘position away from’ and scopos ‘a target foresearch Committee, Tabriz Univer
r (R. Jahanban-Esfahlan).
this work.
niversity of Medical Sciences. Pub
h/
/j.jmhi.2013.03.001shooting at’. Mole described systemic effects of radiotherapy
observed at non-irradiated sites in animals after localized
radiotherapy [1]. Multiple case studies have described the
abscopal effect, with a variety of malignancies including lym-
phoma, papillary adenocarcinoma, and melanoma, adenocar-
cinoma of the oesophagus, chronic lymphocytic leukaemiasity of Medical Sciences, Tabriz, Iran. Tel./fax: +98 0411 3355790;
lished by Elsevier Ltd. Open access under CC BY-NC-ND license.
44 K. Seidi et al.and hepatocellular carcinoma (HCC) [2–13]. Takaya et al. de-
scribed an abscopal effect in toruliform para-aortic lymph
node metastasis in a patient with advanced uterine cervical car-
cinoma. This patient was irradiated on external and intra pel-
vis-cavitary and successfully the cervical carcinoma as well as
the para-aortic lymph node metastases disappeared [14]. In an-
other case study Okuma et al. applied radiotherapy for a 63-
year-old Japanese man following an extended right hepatic
lobectomy with HCC, lung metastasis and a single mediastinal
lymph node metastasis. A computed tomography scan showed
a remarkable reduction of the mediastinal lymph node metas-
tasis and spontaneous shrinking of the lung metastasis
1 month after radiotherapy by the abscopal effect without
any other treatment such as chemotherapy. No recurrence
was observed of either the lung metastasis or the mediastinal
lymph node metastasis during 10 years after the radiotherapy
[12]. It should be noted that the abscopal effect is usually re-
ported following the local radiation of the primary tumour
site, but can be observed as well as after surgery or even fol-
lowing heat treatment (hyperthermia) [15,16].Mechanism of the abscopal effect
Different hypotheses are proposed to explain this phenomenon
[17]. According to the immunological hypothesis, the growth
of a tumour generates a speciﬁc antitumour immune response
(cytokines) induced by local radiation which are released into
the circulation and mediate a systemic antitumour effect [18–
20]. This hypothesis is supported by reports that circulating tu-
mour necrosis factor levels are elevated after radiotherapy and
have coincided with the regression of an HCC situated away
from the radiation ﬁeld [21]. Second, irradiation of a tumour
in one site induces the release of circulating tumour antigen
or inﬂammatory factors, which may then mediate an aug-
mented immune response against non-irradiated, malignant le-
sions expressing similar tumour antigens [20,22]. Supporting
the immunological hypothesis, recently, Postow et al. reported
a case of the abscopal effect in a patient with a metastatic mel-
anoma treated ﬁrst with an immunologic schedule – that was
not effective – and then with radiotherapy. Originally, radio-
therapy was only aimed to ameliorate the pain and other ad-
verse symptoms of the patient but, surprisingly, metastases
began to reduce and even to disappear. Postow et al. observed
temporal correlations between tumour shrinkage and antibody
responses to the cancer/testis antigen NY ESO-1 and changes
in peripheral-blood immune cells after radiation suggesting the
participation of an immunological mechanism [23].
The role of tumour suppressor genes such as p53 is the sec-
ond mechanism proposed by Camphausen et al. They have
developed a model of radiation abscopal effect in C57BL/6
mice by using the LLC and T241 tumours, a model that is,
in part, mediated through p53.They found that the effect
was not caused by weight loss, scatter dose, irradiated circulat-
ing tumour cells or a release of tumour antigens but by the lev-
els of p53 [22]. However they could not deﬁne the entire
mechanism of the abscopal effect.
Lately, the role of non coding RNAs (miRNAs) in the
abscopal effect was proposed by Ilnytskyy et al. While they
were evaluating the sex-speciﬁc response of radiation-sensitive
haematopoietic lymphoid tissues, radiation exposure resulted
in a signiﬁcant and sex-speciﬁc deregulation of microRNAexpression in murine spleen and thymus tissues. They con-
cluded that changes in expression of miR-34a and miR-7
may be effective in important protective mechanisms counter-
acting radiation cytotoxicity and as there was a signiﬁcant in-
crease in the expression of miR-34 they have concluded that
this tumour-suppressor miRNA may show possible regulation
of miRNA expression upon irradiation [24].
The abscopal effect seems to be a particular case of the phe-
nomenon of concomitant tumour resistance (CR) and concom-
itant tumour enhancement/instigation. To clarify these subjects,
we discuss two signiﬁcant papers addressing this phenomenon.
Both papers described circulating tumour-inhibitory and tu-
mour-promoting factors thatwould underlie, respectively, those
phenomena and that could be useful to unveil the nature of the
putative molecules that mediate the abscopal effect.
It has been known for a long time that a tumour-bearing host
is resistant to the growth of secondary tumour implants and
metastasis; this phenomenon is called concomitant tumour resis-
tance (CR). In a recent article, Ruggiero et al. indicated the role
of tyrosine isomers in mechanism of metastasis control as. They
found that meta-tyrosine and ortho-tyrosine, two isomers of
tyrosine that would not be present in normal proteins, are
responsible for CR. They show that in three different murine
models of cancer that generate CR, both meta- and ortho-tyro-
sine inhibited tumour growth. Additionally, both isoforms of
tyrosine blocked metastasis in a fourth model that does not gen-
erate CR but was sensitive to CR induced by other tumours [25].
Themost precious part of Ruggiero’s work was themethod they
applied for the identiﬁcation of such small and rare molecules.
Although previous studies indicated that T-cell-dependent
processes mediate CR in hosts bearing immunogenic small tu-
mours, manifestations of CR induced by immunogenic and
non-immunogenic large tumours have been associated with
an elusive serum factor. However, this factor cannot be identi-
ﬁed because of the very low concentration of the active mole-
cule(s) and the overwhelming amount of tyrosine (Tyr) present
in the puriﬁed antitumour serum fraction, which masked the
existence of other molecules and considerably retarded the
process of characterisation [25]. They used a special schedule
of multiple puriﬁcation steps with dialysis coupled with high-
performance liquid chromatography (HPLC) and ﬁnally iden-
tiﬁed m- and o-Tyr as being responsible for 90% and 10%,
respectively, of the total antitumour activity.
In the case of concomitant tumour enhancement, McAllis-
ter et al. found that human breast carcinomas instigate the
growth of otherwise-indolent tumour cells, micrometastases
and human tumour surgical specimens located at distant ana-
tomical sites. This systemic instigation is accompanied by
incorporation of bone-marrow cells (BMCs) into the stroma
of the distant, once-indolent tumours. They found that secre-
tion of osteopontin by instigating tumours is necessary for
BMC activation and the subsequent outgrowth of the distant
otherwise-indolent tumours [26]. According to this paper, oste-
opontin could mediate tumour-resistance enhancement.
According to these two papers, we propose that there should
be other speciﬁc molecule(s) or macromolecule(s) that enable
the primary tumour to remote-control growth of metastatic tu-
mours in a particular manner, and irradiation, heat therapy or
surgery seems to act as a trigger. We also propose that the fre-
quency of this phenomenon could depend on the tumour type
because it seems that some tumour types are more prone to de-
velop the abscopal effect. This idea provoked by studding 33
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analysis shows that non-solid cancers (lymphoma, leukaemia
and their different sub-types) comprised the major part of all
tumours (n= 15, 46%). Renal cell carcinoma ranked as the
second highest-frequency tumour (n= 8, 24%). HCC
(n= 4, 12%) and melanoma (n= 2, 6%) had a medium fre-
quency. Cervical carcinoma (n= 1, 3%), papillary adenocarci-
noma (n= 1, 3%), Brill Symmers Disease (n= 1, 3%) and
reticulum cell carcinoma (n= 1, 3%) were the lowest fre-
quency or rarely reported tumour types. It was interesting that
there was less or even no report of this effect in cancers such as
the breast, lung or prostate, which are the common cancers
and frequently candidate for radiotherapy in advanced stages.
Furthermore, we propose two precise, practical and well-de-
signed protocols that are capable of testing the proposed
hypotheses. A special design allows one to speciﬁcally screen
and detect any possible molecule(s) or macromolecule(s) that
take the message of ‘Disappearance’ from the primary irradi-
ated tumour to metastatic non-irradiated tumours residing in
any part of the body.
Our proposed protocol can detect any sort of molecule(s)
because of two pivotal considerations: ﬁrst, applying coupled
powerful techniques such as dialysis–HPLC (as successfully
applied by Ruggiero et al. for detection of two isomers of tyro-
sine) for identiﬁcation of low-molecular-weight molecules
which are not easily detectable (MW <12 kDa) and two-
dimensional (2D) electrophoresis for the rest of molecules plusFigure 1 Aboscopal effect: schematic representation of primary tumo
called as aboscopal effect. (A) In absent of aboscopal effect the prim
tumors by releasing activatory factors into blood stream that help t
aboscopal effect, irradiated primary tumor cells inhibit growing of sec
obvious that primary tumor should crosstalk with distant tumors cells t
tumor but the putative connecters for this molecular crosstalk that trig
hypothesize that radiation cause to production of inhibitory molecules
hypotheses fail to reveal possible players involved in this unique pheno
real players.providing quantitative data for up- or down-regulation of
putative molecules and second, considering concomitant
in vivo and in vitro testing, because these conditions always
vary, we predict that if one molecule could not be detected
in vitro, ﬁnally it will be pinned down by in vivo testing.
The Hypothesis
The abscopal effect is known for 60 years but the mechanism
of spontaneous regression of metastatic tumours following
irradiation of the primary tumour site remains a matter of dog-
ma and very little is known about this phenomenon. Based on
current information, we propose that there are particular mol-
ecules or macromolecules that are involved in the abscopal ef-
fect. We also speculate that the frequency of the abscopal
effect varies between different tumour types and the newly dis-
covered molecules or macromolecules can enhance/instigate
the abscopal effect in those tumour types that show a low fre-
quency of this effect.
Testing the hypotheses
Determination of origin of abscopal effect
Here we describe a proposed method to test if the abscopal ef-
fect occurs under special situations or it is a phenomenon thatr behavior on distant tumors following irradiation: a phenomenon
ary tumor cell induce seeding and growing of distant secondary
o nourish growing secondary tumor cells. (B) In presence of an
ondary tumors by an unknown mechanism. For this purpose, it is
hat once upon a time some of those cells were a part of this primary
ger following local radiation of primary tumor is unknown. Some
such as P53 or inhibitory cytokines such as TNFa but all proposed
menon. Our proposed design for aboscopal effect will uncover the
Figure 2 Our proposed model for seeking the putative factors that may play role in aboscopal effect.
46 K. Seidi et al.depends on the primary tumour. Further if it could be ad-
dressed that the abscopal effect is regulated by the primary tu-
mour, then the second issue will be identiﬁcation of factors
that are responsible for this amazing effect (Fig. 1).
The main strategy of how we can reveal factor(s) that is
responsible for crosstalk between tumour cells is depicted
in Fig. 2. For this, we recommend 20 inbred immunodeﬁ-
cient mice (such as BALB/c or nude mice) to omit the effect
of non-identical genetic material as a confounding factor.
Then, half of them will be considered as the healthy group
(control) without developing any tumour while the rest will
comprise the treated group (abscopal effect model) and theyshould develop a metastatic tumour for studying the absco-
pal effect. For this case, the preferred cell line is renal cell
carcinoma (or melanoma) that had a high frequency of the
abscopal effect in case studies. Parallel in vivo and in vitro
testing should be carried out by using the same cell line
(renal cell carcinoma).
The ﬁrst issue will be determination of the origin of the
abscopal effect. In other words, do tumour cells control and
regulate growth of secondary tumours following radiotherapy
or is it radiotherapy that is capable of causing some genomic
changes that could mediate the abscopal effect or does this
phenomenon have a root in the host’s own nature or maybe
Figure 3 Our proposed model for uncovering the general or tumor type speciﬁc manner of aboscopal effect.
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studying a healthy group as control along with an acceptable
model of the abscopal effect as the treated group will be essen-
tial. The control group will bear no tumour, but will be ex-
posed to the same doses of irradiation as the treated group
will. Irradiation will continue in deﬁned doses and intervals
for both groups till a sign of the abscopal effect such as shrink-
ing or full disappearing of metastatic tumour conﬁrmed by
means of a real-time in vivo imaging technique such as mag-
netic resonance imagining (MRI) or biochemoluminescence
(BCL). We postulate that any possible connector(s) between
primary and metastatic tumours should be detectable in the
serum immediately following observation of the abscopal ef-
fect and it is not necessary to test tumour tissues. Then, serum
isolation of the studied groups and the cytotoxicity analysis of
parallel in vivo and in vitro tests will be the next tasks.
The ﬁnal step will be proper interpretation of the obtained
results. In this way, if the serum of control mice had cytotoxic
effects on the cultured renal cell carcinoma cell line (in vitro) or
could save mice with renal cell carcinoma (in vivo), it is not
only tumour cells which are implicated in development of
aboscpal effect but other factors can mediate this effect in
the absence of tumour cells. However, if the serum of control
mice showed no cytotoxicity on cultured tumour cells norcould the metastatic mice survive then it can be concluded that
the abscopal effect is a phenomenon that depends on the nat-
ure of primary tumour cells and the serum of treated mice
should have a cytotoxic effect on the cultured renal cell carci-
noma cell line or can cause survival of mice with metastatic tu-
mours. Then, dialysis will be applied to separate components
of serum with cytotoxic effects. Serum compounds that repre-
sent an MW >12 kDa will be candidates for 2D gel electro-
phoresis and matrix-assisted laser desorption/ionisation-time
of ﬂight mass spectrometry (MALDI-TOFMS) and those with
an MW <12 kDa will be candidates for HPLC. Two-dimen-
sional analysis will identify the proteins and also will provide
fold-change difference in protein expression level before and
after radiotherapy in both groups. In case the serum lacks rare
or hydrophobic membrane proteins, 2D is the proper method
for identiﬁcation of our expected molecules. HPLC analysis
will be applied for detection of lower-molecular-weight com-
pounds based on their special retention times. It is expected
that HPLC will detect all small molecules present in serum
such as amino acids, lipids, polyamine, ceramids and any tiny
molecules.
Finally, comparison between results of HPLC and 2D-MS
serum proﬁle of control mice with treated mice will identify
any putative factor(s) involved in the abscopal effect.
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The aim of the second hypothesis will be to test if the fre-
quency of the abscopal effect varies between different tumours
and if so then it can be concluded that there are speciﬁc factors
that play role in the abscopal effect that should be identiﬁed.
For this purpose ﬁve metastatic BALB/c mice models rep-
resented as A, B, C, D and E will be established (Fig. 3). Each
of them will be inoculated with tumour cells that have a differ-
ent frequency of the abscopal effect. In this way, the A mice
will be inoculated with chronic lymphocytic leukaemia or renal
cell carcinoma which show a high frequency of the abscopal ef-
fect according to case reports, B mice (moderate frequency)
will be treated with HCC or melanoma cell lines. C, D and
E mice could be treated by low or no report of abscopal effect
tumour cells such as breast/lung/prostate/cervical/colon, etc.
We recommend considering three cell lines for rare reports
to reduce the possible unwanted errors for missed or ignored
case-study reports of tested cell lines.
After irradiation of the primary tumour site and conﬁrma-
tion of the abscopal effect, serum from all ﬁve groups will be
isolated to test its cytotoxicity.
It is expected that rare cell lines (models C, D and E) could
not develop any abscopal effect or show signiﬁcant delay in
developing this phenomenon in comparison to model B and
model A and it is expected that model A could develop the
abscopal effect earlier than model B.
Thenext stepwill be identiﬁcationofmolecules present in ser-
um and which mediate the abscopal effect. We propose to treat
the serum of each group concomitantly on cultured tumour cells
andmicemodels bearing the same sort of tumours. For example,
if A is a renal cell carcinoma tumour cell line that was injected
into inbredBALB/cmice to develop ametastatic tumour (model
A), following observation of the abscopal effect, the cytotoxicity
of serum A will be tested on ﬁve tumour cell lines (A and A, A
and B, A and C, A and D, A and E) in parallel in vivo and
in vitro. If results showed that serum A has the highest effective-
ness on own cell line rather than others, then it can be concluded
that the abscopal effect is regulated by speciﬁc factors and it de-
pends on the sort of tumour it has originated from. However, if
serumA has the same effectiveness in killing all types of tumour
cells then it can be concluded that the abscopal effect is down-
regulated by general pathways such as immune responses and
is not tumour-speciﬁc. This process will be repeated for all ﬁve
tumour cells. Moreover comparison of results between ﬁve tu-
mour cell lines will reveal which tumour has the highest rate of
developing the abscopal effect and so this phenomenon is re-
stricted to special tumours; however, if the ﬁve studied tumour
cell lines represent an equal rate of developing the abscopal effect
then this observation will double conﬁrm previous results that
the abscopal effect is regulated by a general mechanism and
factor(s).
Discussion and conclusion
At the moment, maybe it does not look probable that you could
neutralise and remote control the growth of any metastatic cells
– hidden in any inaccessible part of the body – by targeting only
the primary tumour cells with a deﬁned factor(s) as the same
phenomenon naturally occurs in spontaneous tumour regres-
sion events such as the abscopal effect. Here, we postulate thatthere is a common language between tumour cells that is not
translatable for cells other than cancerous ones.
Because there is no established model to study the abscopal
effect, more detailed information cannot be obtained about
possible factors that are necessary to elicit this clinically rele-
vant phenomenon. It is hoped that the hypotheses presented
here and the corresponding protocols can ﬁnally lead to intro-
duction of these factor(s) into cancer research and help to gen-
erate potent treatment strategies worthy of being translated
into the clinic for curing the advanced metastatic cancers.
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None declared.Overview Box
First Question: What do we already know about the
subject?
The abscopal effect is a phenomenon that was discov-
ered many years ago. According to this unexplainable ef-
fect, treatment with radiotherapy directly localized on a
tumour can profoundly affect tumour cells in other tissues
far from the radiated part; but how this is possible remain
unclear for a long time. For now, no study has managed
to describe what exactly happens and which factors medi-
ate this astonishing effect.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
At the moment, there is no protocol that could evalu-
ate all aspects of the aboscopal effect and could ﬁnally
introduce factors underlying this unique phenomenon.
Our proposed protocol has a precise and practical design
that can evaluate any possible factor that may play a role
in this phenomenon. By discovering the factors responsi-
ble for this interesting effect, maybe the fatal face of can-
cer which is metastasis could be controlled.
Third Question: Among numerous available studies,
what special further study is proposed for testing the idea?
In this paper we have proposed two critical questions
answering which may reveal the mediators of the abosco-
pal effect. Furthermore we have proposed a protocol that
leads us to the answer to the proposed questions. So the
proposed questions and the corresponding proposed pro-
tocol both are quite novel ideas. Of course the proposed
designs seem a bit difﬁcult to handle and there are more
complex steps that should be done very precisely and
these protocols will be rather high cost and time consum-
ing but it worth to test and publish the observed valuable
precious results.
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